5 Insightful Analyst Questions From Tandem Diabetes's Q2 Earnings Call

Tandem Diabetes Care’s second quarter results were met with a significant negative market reaction, reflecting investor concerns despite the company’s revenue surpassing Wall Street expectations. Management attributed the quarter’s performance to rising pump and supply volumes, higher average selling prices through channel management, and double-digit growth in renewals. CEO John Sheridan acknowledged that while U.S. pump shipments and customer retention remained strong, continued investments in business transformation and competitive pressures impacted operating margins, stating that “some of the adjustments to the U.S. numbers really acknowledge that a number of these initiatives are still in process, and that has delayed some of the benefit.”

Is now the time to buy TNDM? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Tandem Diabetes’s Q2 Earnings Call

• Matthew Stephan Miksic (Barclays): Asked about the impact of potential CMS policy changes on Tandem’s business. CFO Leigh Vosseller responded that Medicare represents less than 10% of sales and the proposed changes could actually encourage pump adoption, so the net business effect is expected to be limited or positive.
• Matthew Charles Taylor (Jefferies): Inquired about the scale and timing of pharmacy channel expansion. Vosseller outlined that pharmacy contributed a few million dollars in Q2, coverage is at 30%, and the company expects further contracts to expand reach, with meaningful benefit as t:slim supplies enter the channel in Q4.
• William John Plovanic (Canaccord Genuity): Queried the mix of new patient starts versus renewals. Vosseller explained that U.S. renewals grew double digits and now represent more than half of shipments, while new starts from MDI conversions are outpacing competitive conversions.
• Travis Lee Steed (Bank of America Securities): Sought specifics on the lowered U.S. guidance and the split between commercial transformation delays and new competition. CEO John Sheridan acknowledged both factors are contributing, with benefits from new systems and expanded sales teams not yet fully realized.
• Anthony Charles Petrone (Mizuho Americas): Asked about the contribution of pharmacy channel stocking in Q2. Vosseller stated it was a few million dollars and noted that this inventory dynamic may lead to flattish revenues from Q2 to Q3 due to seasonality and timing.

Catalysts in Upcoming Quarters

In future quarters, the StockStory team will be closely monitoring (1) the pace of pharmacy channel adoption and the rollout of t:slim supplies, (2) the impact of direct sales transitions and pump renewals in international markets, and (3) the effectiveness of commercial system upgrades and sales force expansion in the U.S. Progress on product launches, especially the Mobi platform and Libre 3 sensor integration, will also be key for assessing execution.

Tandem Diabetes currently trades at $11.14, down from $14.45 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

The Best Stocks for High-Quality Investors

When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.